Multiple System Atrophy Market to Grow with a CAGR of 3.11% through 2028

The increasing in frequency of neurodegenerative diseases is expected to drive the Global Multiple System Atrophy Market growth in the forecast period, 2024-2028.

According to TechSci Research report, “Multiple System Atrophy Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2028”, the Global Multiple System Atrophy Market stood at USD 149.73 Million in 2022 and is anticipated to grow with a CAGR of 3.11% through 2028. This disorder poses significant threat to a patient's quality of life, obstructing their day-to-day activities at large. MSA life expectancy may vary from person to person but on an average a patient may live 6-9 years from the time of detection. It is crucial to determine the MSA risk factors at an early stage so that professionals can accurately formulate MSA coping strategies. Medical scientists and healthcare professionals have expedited their MSA research & development activities with an aim to facilitate effective drug development. The growing disease burden is indeed pointing towards a global health hazard which needs to be tackled effectively. Major shy drager syndrome symptoms include muscle stiffness, postural deformity, dizziness, orthostatic hypotension, sexual dysfunction, bowel issues, slurred speech, behavioural changes, and cognitive issues. MSA outcomes can be severe if the symptoms go unnoticed.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Multiple System Atrophy Market”

The Global Multiple System Atrophy Market is segmented into Diagnosis, Age, End User and company.

Based on the Diagnosis, the Magnetic Resonance Imaging segment is anticipated to witness substantial market growth throughout the forecast period. Magnetic Resonance Imaging (MRI) is poised to be a catalyst for the growth of the Global Multiple System Atrophy (MSA) Market. As a non-invasive and advanced imaging technique, MRI plays a pivotal role in the early and accurate diagnosis of MSA, contributing to improved patient outcomes and streamlined clinical trials. MRI enables the visualization of structural abnormalities and changes in the brain associated with MSA, providing clinicians with valuable insights into the disease's progression. This diagnostic precision is crucial for distinguishing MSA from other neurodegenerative disorders and facilitating prompt intervention. In addition to its diagnostic utility, MRI is becoming increasingly instrumental in advancing MSA research and drug development. It serves as a key tool for monitoring treatment efficacy and disease progression in clinical trials, offering objective and quantifiable measures that enhance the efficiency of these studies. The widespread adoption of MRI technology in both clinical practice and research initiatives creates a synergistic effect, fostering collaboration between healthcare institutions, pharmaceutical companies, and imaging technology developers.

Based on the End User segment, the Hospitals segment has been the dominant force in the market. Hospitals are positioned as key drivers in fueling the growth of the Global Multiple System Atrophy (MSA) Market. As primary hubs for healthcare delivery, hospitals play a central role in the diagnosis, treatment, and management of MSA. The rising prevalence of MSA, coupled with increasing awareness and diagnostic capabilities, results in a growing number of patients seeking care in hospital settings. Hospitals contribute significantly to the expansion of the MSA market by serving as crucial centers for clinical trials and research initiatives. These institutions often collaborate with pharmaceutical companies, research organizations, and other stakeholders to conduct studies, advancing our understanding of the disease and facilitating the development of novel therapeutic interventions. Moreover, the demand for specialized MSA care within hospital settings fosters the growth of dedicated neurology departments and clinics. This specialization not only enhances patient outcomes but also attracts investments in infrastructure, technology, and healthcare professionals, creating a robust ecosystem for MSA-focused advancements.

Major companies operating in Global Multiple System Atrophy Market are

• Biohaven Ltd.
• Theravance Biopharma
• Sumitomo Dainippon Pharma Co., Ltd.
• Alterity Therapeutics
• AstraZeneca plc.
• Biogen
• Merck & Co., Inc.
• Neuropore Therapies, Inc.
• WaveBreak Therapeutics
• Newron Pharmaceuticals SPA

Download Free Sample Report

Customers can also request 10% free customization on this report

“The Global Multiple System Atrophy (MSA) Market is propelled by several key drivers shaping its growth trajectory. Firstly, increasing awareness and early diagnosis initiatives have elevated patient identification, driving demand for MSA therapeutics. Additionally, a surge in research and development activities focused on novel treatment modalities and disease-modifying interventions has fueled market expansion. The growing elderly population, particularly in developed regions, contributes significantly to the rising prevalence of MSA, bolstering market prospects. Furthermore, collaborative efforts between pharmaceutical companies and research institutions enhance the development of innovative therapies. Technological advancements in diagnostic tools and biomarker identification also play a pivotal role in advancing MSA treatment options. These collective factors create a conducive environment for sustained market growth, fostering opportunities for stakeholders in the global MSA market.” said Mr. Karan Chechi, Research Director with TechSci Research, a research-based management consulting firm.

“Multiple System Atrophy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Diagnosis (Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT), Tilt Table Test, Others), By Age (Pediatric, Adults, Geriatric), By End User (Hospitals, Ambulatory Surgical Centers, Others), By Region, By Competition”, has evaluated the future growth potential of Global Multiple System Atrophy Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Multiple System Atrophy Market.

Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: [email protected]